Advertisement

Pleural Neoplasms

  • Samuel P. Hammar
  • John W. Bolen

Abstract

In contrast to primary or metastatic neoplasms in the lung parenchyma, pleural neoplasms are uncommon. Pleural tumors are frequently associated with a pleural effusion; they are often difficult to diagnose and must be distinguished from primary or metastatic carcinomas involving the pleura and from benign reactive processes causing pleural thickening. A correct diagnosis is important so that appropriate therapy, although it may be only palliative, can be instituted. The most common and most important primary pleural neoplasm is mesothelioma, which has gained notoriety in recent years because of its etiologic relationship to asbestos exposure and the extensive litigation that has resulted from personal injury lawsuits filed because of asbestos-induced lung disease. Other neoplasms such as soft tissue sarcomas and leukemia-lymphoma may also involve the pleura and must be differentiated from mesotheliomas. This chapter discusses pleural neoplasms with a primary emphasis on mesotheliomas.

Keywords

Hyaluronic Acid Mesothelial Cell Pleural Fluid Malignant Pleural Mesothelioma Malignant Mesothelioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aisner J, Wiernick PH. Malignant mesothelioma. Current status and future prospects. Chest 1978; 74: 438 – 443.PubMedGoogle Scholar
  2. 2.
    Chahinian AP. Malignant mesothelioma. In: Holland JF, Frei E III, eds. Cancer Medicine. Philadelphia: Lea & Febiger, 1982: 1744 – 1751.Google Scholar
  3. 3.
    Wagner E. Das tuberkelahnliche lymphadenom. Arch Heilk 1870; 11: 495 – 525.Google Scholar
  4. 4.
    Robertson HE. “Endothelioma” of the pleura. Am JCancer 1924;8:317–375.Google Scholar
  5. 5.
    Klemperer P, Rabin CB. Primary neoplasms of pleura: report of 5 cases. Arch Pathol 1931; 11: 385 – 412.Google Scholar
  6. 6.
    Stout AP, Murray MR. Localized pleural mesothelioma: investigation of its characteristics and histogenesis by the method of tissue culture. Arch Pathol 1942; 34: 951–964.Google Scholar
  7. 7.
    Foster EA, Ackerman LV. Localized mesotheliomas of the pleura: the pathologic evaluation of 18 cases. Am J Clin Pathol 1960; 34: 349 – 364.PubMedGoogle Scholar
  8. 8.
    Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in North Western Cape Province. Br J Ind Med 1960; 17: 260 – 271.PubMedGoogle Scholar
  9. 9.
    Selikoff IJ, Churg J, Hammond EC. Relation between exposure to asbestos and mesothelioma. N Engl J Med 1965; 272: 560 – 565.PubMedGoogle Scholar
  10. 10.
    Wedler HW. Uber den Lungenkrebs bei Asbestose. Dtsch Arch Klin Med 1943; 191: 189 – 209.Google Scholar
  11. 11.
    Mallory TB, Castleman B, Parris EE. Case records of the Massachusetts General Hospital #33111. N Engl J Med 1947; 236: 407 – 412.Google Scholar
  12. 12.
    Weiss A. Pleurakrbs bei Lungenasbestose, in vivo morphologisch Geishert. Medizienische 1953; 3: 93 – 94.Google Scholar
  13. 13.
    Leicher F. Primarer deckzellen Tumor des Bauchtells bei Asbestose. Arch Gewerbe Pathol Gewerbehyg 1954; 13: 382 – 392.Google Scholar
  14. 14.
    Keal EE. Asbestosis and abdominal neoplasms. Lancet 1960; 2: 1211 – 1216.PubMedGoogle Scholar
  15. 15.
    Goodwin MC. Diffuse mesotheliomas with comment on their relationship to localized fibrous mesotheliomas. Cancer 1967; 10: 298 – 319.Google Scholar
  16. 16.
    Motley RL. The lid comes off. Trial 1980; 15: 21 – 24.Google Scholar
  17. 17.
    Brodeur P. Expendable Americans. New York: Viking, 1974.Google Scholar
  18. 18.
    Brodeur P. The asbestos industry on trial. I-A failure to warn. II-Discovery. III-Judgement. IV-Bankruptcy. New Yorker 1985;61:49–52+ (Je 10); 45–48+ (Je 17); 37–41+ (Je 24); 36–38+ 01 1 ).Google Scholar
  19. 19.
    McDonald AD, Harper A, El Attar DA, McDonald JC. Epidemiology of primary malignat mesothelial tumors in Canada. Cancer 1970; 26: 914 – 919.PubMedGoogle Scholar
  20. 20.
    Theriault GP, Grand-Bois L. Mesothelioma and asbestos in the province of Quebec, 1969–1972. Arch Environ Health 1978; 33: 15 – 19.PubMedGoogle Scholar
  21. 21.
    Biava PM, Ferri R, Spacal B, et al. Cancro de lovora a Trieste: Il mesothelioma della pleura. Sapere 1976; 79: 41 – 45.Google Scholar
  22. 22.
    Greenberg M, Lloyd-Davies TA. Mesothelioma register 1967–1968. Br J Ind Med 1974; 31: 91 – 104.PubMedGoogle Scholar
  23. 23.
    McDonald AD, McDonald JC. Malignant mesothelioma in North America. Cancer 1980; 46: 1650 – 1656.PubMedGoogle Scholar
  24. 24.
    Cutler SJ, Young JL. Third National Cancer Survey: incidence data. Natl Cancer Inst Monogr 1975; 41: 442.Google Scholar
  25. 25.
    Bruckman L, Rubino RA, Christine B. Asbestos and mesothelioma incidence in Connecticut. J Air Pollut Control Assoc 1977; 27: 121 – 126.PubMedGoogle Scholar
  26. 26.
    Churg A. Malignant mesothelioma in British Columbia in 1982. Cancer 1985; 55: 672 – 674.PubMedGoogle Scholar
  27. 27.
    McDonald JC, McDonald AD. Epidemiology of mesothelioma from estimated incidence. Prey Med 1977; 6: 426 – 446.Google Scholar
  28. 28.
    Hughes JM, Weill H. Asbestos exposure-quantitative assessment of risk. Am Rev Respir Dis 1986; 133: 5 – 13.PubMedGoogle Scholar
  29. 29.
    Selikoff IJ, Hammond EC, Seidman H. Mortality experience of insulation workers in the United States and Canada 1943–1976. Ann NY Acad Sci 1979; 330: 9 1116.Google Scholar
  30. 30.
    Wagner JC. Mesothelioma and mineral fibers. Cancer 1986; 57: 1905 – 1911.PubMedGoogle Scholar
  31. 31.
    Rom WM, Lockey JE. Diffuse malignant mesothelioma: a review. West J Med 1982; 137: 548 – 554.PubMedGoogle Scholar
  32. 32.
    Legha SS, Muggia FM. Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med 1977; 87: 613 – 621.PubMedGoogle Scholar
  33. 33.
    Borow M, Conston A, Livornese L, Schalet N. Mesotheliorna following exposure to asbestos: a review of 72 cases. Chest 1973; 64: 641 – 646.PubMedGoogle Scholar
  34. 34.
    Cochrane JC, Webster I. Mesothelioma in relation to asbestos fibre exposure. A review of 70 serial cases. S Afr Med J 1978; 54: 279 – 281.PubMedGoogle Scholar
  35. 35.
    Tagnon I, Blot WJ, Stroube RB, et al. Mesothelioma associated with the shipbuilding industry in coastal Virginia. Cancer Res 1980; 40: 3875 – 3879.PubMedGoogle Scholar
  36. 36.
    Whitwell F, Rawcliffe RM. Diffuse malignant pleural mesothelioma and asbestos exposure. Thorax 1971; 26: 6 – 22.PubMedGoogle Scholar
  37. 37.
    Hammar S, Bolen JW, Remington F, Bockus D, Friedman S. A clinicopathologic correlation of 151 cases of mesothelioma studied by electron microscopy and immunohistochemistry (in preparation). Submitted to Ultra Pathol, 1987.Google Scholar
  38. 38.
    Taylor RA, Johnson LP. Mesothelioma: current perspectives. West J Med 1981; 134: 379 – 383.PubMedGoogle Scholar
  39. 39.
    Vogelzang NJ, Schultz SM, Iannucci AM, Kennedy BJ. Malignant mesothelioma: the University of Minnesoto experience. Cancer 1984; 53: 377 – 383.PubMedGoogle Scholar
  40. 40.
    Newhouse ML, Thompson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med 1965; 22: 261 – 269.PubMedGoogle Scholar
  41. 41.
    Peto J, Henderson BE, Pike MC. Trends in mesothelioma in the United States and the forecast epidemic due to asbestos exposure during World War II. In: Peto R, Schneiderman M, eds. Quantification of occupational cancer. Banbary Report 9. New York: Cold Spring Harbor Laboratory:51–69.Google Scholar
  42. 42.
    Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases. Cancer 1982; 50: 2423 – 2432.PubMedGoogle Scholar
  43. 43.
    Oels HC, Harrison EG, Carr DT, Bernatz PE. Diffuse malignant mesothelioma of the pleura: a review of 37 cases. Chest 1971; 60: 564–470.Google Scholar
  44. 44.
    Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: review of 123 patients. Cancer 1982; 49: 2431 – 2435.PubMedGoogle Scholar
  45. 45.
    Ratzer ER, Pool JL, Melamed MR. Pleural mesotheliomas: clinical experiences with thirty-seven patients. Am J Radiol 1967; 99: 863 – 880.Google Scholar
  46. 46.
    Newhouse ML, Berry G. Patterns of mortality in asbestos factory workers in London. Ann NY Acad Sci 1979; 330: 53 – 60.PubMedGoogle Scholar
  47. 47.
    Newhouse ML, Berry G. Predictions of mortality from mesothelial tumours in asbestos factory workers. Br J Ind Med 1976; 33: 147 – 151.PubMedGoogle Scholar
  48. 48.
    Epler GR, Gerald MXF, Gaensler EA, Carrington CB. Asbestos-related disease from household exposure. Respiration 1980; 39: 229 – 240.PubMedGoogle Scholar
  49. 49.
    Chen W, Mottet NK. Malignant mesothelioma with minimal asbestos exposure. Hum Pathol 1978; 9: 253 – 258.PubMedGoogle Scholar
  50. 50.
    Anderson HA, Lils R, Daum SM, et al. Asbestosis among household contacts of asbestos factory workers. Ann NY Acad Sci 1979; 330: 387 – 399.PubMedGoogle Scholar
  51. 51.
    Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet 1978; 1: 1061 – 1063.PubMedGoogle Scholar
  52. 52.
    Stanton MF, Wrench C. Mechanisms of mesothelioma induction with asbestos and fibrous glass. JNCI 1972; 48: 797 – 821.PubMedGoogle Scholar
  53. 53.
    Stanton MF, Layord M, Tegeris A, et al. Relation of particle dimension to carcinogenicity in amphibole asbestos and other fibrous minerals. JNCI 1981; 67: 965–975.Google Scholar
  54. 54.
    Gross P. Is short fibered asbestos dust a biological hazard? Arch Environ Health 1974; 29: 115 – 117.PubMedGoogle Scholar
  55. 55.
    Churg A, Wiggs B. Fiber size and number in amphibole asbestos-induced mesothelioma. Am J Pathol 1984; 115: 437 – 442.PubMedGoogle Scholar
  56. 56.
    Weiss W. Mortality of a cohort exposed to chrysotile asbestos. J Occ Med 1977; 19: 737 – 740.Google Scholar
  57. 57.
    McDonald JC, Liddell FDK, Gibbs GW, Eyssen GE, McDonald AD. Dust exposure and mortality in chrysotile mining, 1910–75. Br J Ind Med 1980; 37: 11 – 24.PubMedGoogle Scholar
  58. 58.
    McDonald AD, Fry JS. Mesothelioma and fiber type in three American asbestos factories-preliminary report. Scand J Work Environ Health 1982; 8 (Suppl): 5558.Google Scholar
  59. 59.
    Acheson ED, Gardner MJ, Pippard EC, Grime LP. Mortality of two groups of women who manufactured gas masks from chrysotile and crocidolite asbestos: a 40 year follow-up. Br J Ind Med 1982; 39: 344 – 348.PubMedGoogle Scholar
  60. 60.
    Dement JM, Harris RL, Symons MJ, Shy CM. Exposure and mortality among chrysotile asbestos workers. Part II. Mortality. Am J Ind Med 1983; 4: 421 – 433.PubMedGoogle Scholar
  61. 61.
    Browne K, Smither WJ. Asbestos related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 1983; 40: 145 – 152.PubMedGoogle Scholar
  62. 62.
    Berry G, Newhouse ML. Mortality of workers manufacturing friction materials using asbestos. Br J Ind Med 1983; 40: 1 – 7.PubMedGoogle Scholar
  63. 63.
    Acheson ED, Gardner MJ, Bennet C, Winter PD. Mesothelioma in a factory using amosite and chrysotile asbestos. Lancet 1981; 2: 1403 – 1406.PubMedGoogle Scholar
  64. 64.
    Churg A, Wiggs B, Depaoli L, Kampe B, Stevens B. Lung asbestos content in chrysotile workers with mesothelioma. Am Rev Respir Dis 1984; 130: 1042 – 1045.PubMedGoogle Scholar
  65. 65.
    Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 1983; 77: 321 – 343.PubMedGoogle Scholar
  66. 66.
    Jaurand MC, Bignon J, Sebastien P, Goni J. Leaching of chrysotile asbestos in human lungs: correlation with in vitro studies using rabbit alveolar macrophages. Environ Res 1977; 14: 245 – 254.PubMedGoogle Scholar
  67. 67.
    Peterson JT Jr, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma: a review. Cancer 1984; 54: 951 – 960.PubMedGoogle Scholar
  68. 68.
    Baris YI. Pleural mesotheliomas and abestos pleurisies due to environmental asbestos exposure in Turkey: an analysis of 120 cases. Hacettepe Bull Med/Surg 1975; 8: 165 – 185.Google Scholar
  69. 69.
    Baris YI, Sahin AA, Ozesmi M, et al. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax 1978; 33: 181 – 192.PubMedGoogle Scholar
  70. 70.
    Artvinli M, Baris YI. Malignant mesotheliomas in a small village in the Anatolian region of Turkey: an epidemiologic study. JNCI 1979; 63: 17 – 22.PubMedGoogle Scholar
  71. 71.
    Baris YI, Saracci R, Simonato L, Skidmore JW, Artvinli M. Malignant mesothelioma and radiological chest abnormalities in two villages in central Turkey. Lancet 1981; 1: 984 – 987.PubMedGoogle Scholar
  72. 72.
    Artvinli M, Baris YI. Environmental fiber-induced pleuro-pulmonary diseases in an Anatolian village: an epidemiologic study. Arch Environ Health 1982; 37: 177 – 181.PubMedGoogle Scholar
  73. 73.
    Lillis R. Fibrous zeolites and endemic mesothelioma in Cappadocia, Turkey. J Occup Med 1981; 23: 548 – 550.Google Scholar
  74. 74.
    Sebastien P, Gaudichet A, Bignon J, Baris YI. Zeolite bodies in human lungs from Turkey. Lab Invest 1981; 44: 420 – 425.PubMedGoogle Scholar
  75. 75.
    Wagner JC, Skidmore JW, Hill RJ, Griffiths DM. Erionite exposure and mesotheliomas in rats. Br J Cancer 1985; 51: 727 – 750.PubMedGoogle Scholar
  76. 76.
    Rohl AN, Langer AM, Moncure G, Selikoff IJ, Fischbein A. Endemic pleural disease associated with exposure to mixed fibrous dust in Turkey. Science 1982; 216: 518–520.Google Scholar
  77. 77.
    Hillerdal G, Berg J. Malignant mesothelioma secondary to chronic inflammation and old scars: two new cases and review of the literature. Cancer 1985; 55: 1968 1972.Google Scholar
  78. 78.
    Austin MB, Fechner RE, Roggli VL. Pleural malignant mesothelioma following Wilms’ tumor. Am J Clin Pathol 1986; 86: 227 – 230.PubMedGoogle Scholar
  79. 79.
    Anderson KA, Hurley WC, Hurley BT, Ohrt DW. Malignant pleural mesothelioma following radiotherapy in a 16-year-old boy. Cancer 1985; 56: 273 – 276.PubMedGoogle Scholar
  80. 80.
    Talerman A, Montero JR, Chilcote RR, Okagaki T. Diffuse malignant peritoneal mesothelioma in a 13-yearold girl: report of a case and review of the literature. Am J Surg Pathol 1985; 9: 73 – 80.PubMedGoogle Scholar
  81. 80a.
    Fraire AE, Cooper S, Greenberg SD, Buffler PA, Langston C. Mesothelioma of childhood. Lab Invest 1987; 56: 25A.Google Scholar
  82. 81.
    Lynch HT, Katz D, Markvicka SE. Familial mesothelioma: review and family study. Cancer Genet Cytogenet 1985; 15: 25 – 35.PubMedGoogle Scholar
  83. 82.
    Martensson G, Larsson S, Zettergren L. Malignant mesothelioma in two pairs of siblings: is there a hereditary predisposing factor? Eur J Respir Dis 1984; 65: 179 – 184.PubMedGoogle Scholar
  84. 83.
    Hammar S, Bolen J, Bockus D, Remington F, Friedman S. Malignant mesotheliomas in three brothers exposed to asbestos. (Submitted for publication, 1987.)Google Scholar
  85. 84.
    McCaughey WTE. Criteria for the diagnosis of diffuse mesothelial tumors. Ann NY Acad Sci 1965; 132: 603 – 613.PubMedGoogle Scholar
  86. 85.
    Kannerstein M, McCaughey WTE, Churg J, Selikoff IJ. A critique for the diagnosis of diffuse malignant mesothelioma. Mt Sinai J Med (NY) 1977; 44: 485 – 494.Google Scholar
  87. 86.
    Kannerstein M, Churg J, McCaughey WTE. Asbestos and mesothelioma: a review. Pathol Annu 1978: 81 – 130.Google Scholar
  88. 87.
    Adams VI, Unni KK, Diffuse malihnant mesothelioma of pleura: diagnostic criteria based on an autopsy atudy. Am J Clin Pathol 1984; 82: 15 – 23.PubMedGoogle Scholar
  89. 88.
    McCaughey WTE, Kannerstein M, Churg J. Tumors and pseudotumors of the serous membranes. Washington D.C.: Armed Forces Institute of Pathology, 1985.Google Scholar
  90. 89.
    Yousem SA, Hochholzer L. Malignant mesotheliomas with osseous and cartilaginous differentiation. Arch Pathol Lab Med 1987; 111: 62 – 66.PubMedGoogle Scholar
  91. 90.
    Kannerstein M, Churg J. Desmoplastic diffuse malignant mesothelioma. In: Fenoglio CM, Wolff M, eds. Progress in surgical pathology. New York: Mason, 1980: 19 – 29.Google Scholar
  92. 91.
    Cantin R, Al-Jabi M, McCaughey WTE. Desmoplastic diffuse mesothelioma. Am J Surg Pathol 1982; 6: 215 – 222.PubMedGoogle Scholar
  93. 92.
    Dardic I, Al-Jabi M, McCaughey WTE, Srigley JR, van Nostrand AWP, Ritchie AC. Ultrastructure of poorly differentiated diffuse epithelial mesotheiomas. Ultrastruct Pathol 1984; 7: 151 – 160.Google Scholar
  94. 93.
    Said JW, Nash G, Banks-Schlegel S, Sassoon AF, Shitaku IP. Localized fibrous mesothelioma: an immunohistochemical and electron microsopic study. Hum Pathol 1984; 15: 440 – 443.PubMedGoogle Scholar
  95. 94.
    Briselli M, Mark EJ, Dikerson GR. Solitary fibrous tumors of the pleura: eight new cases and review of 360 cases in the literature. Cancer 1982: 180 – 216.Google Scholar
  96. 95.
    Cook HC. Carbothydrates. In: Bancroft JD, Stevens A, eds. Theory and practice of histological techniques. New Yorl: Churchill Livingstone, 1982: 180 – 216.Google Scholar
  97. 96.
    Benjsmin CJ, Ritchie AC. Histological staining for the diagnosis of mesothelioma. Am JMed Technol 1982; 48: 905 – 908.Google Scholar
  98. 97.
    Hsu SM, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577 – 580.PubMedGoogle Scholar
  99. 98.
    Sun TT, Eichner R, Nelson WG, et al. Keratin classes: molecular markers for different types of epithelial differentiation. J Invest Dermatol 1983; 81: 109–115 (suppl).Google Scholar
  100. 99.
    Moll R, Franke WW, Schiller DL, et al. The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11 – 24.PubMedGoogle Scholar
  101. 100.
    Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue: a light-microscopic, ultructural and immunocytochemical study. Am J Surg Pathol 1986; 10: 34 – 47.PubMedGoogle Scholar
  102. 101.
    Bolobel GA, Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985; 121: 235 – 247.Google Scholar
  103. 102.
    Momtag AG, Pinkus GS, Coson JM. Immunoreactivity for keratin proteins in sarcomatoid diffuse malignant mesothelioma: adiagonstic discriminant among spindle cell tumors. Lab Invest 1985; 52: 44A.Google Scholar
  104. 103.
    Said JW, Nash G, Banks-Schlegel S, Sassoon AF, Shintaku IF. Keratin in human lung tumors: patterns of localization of different molecular-weight keratin proteins. Am J Pathol 1983; 113: 27 – 32.PubMedGoogle Scholar
  105. 104.
    Watts AE, Said JW, Shintaku IP, Sassoon AF, Banks-Schlegel S. Keratins of different molecular weight in exfoliated mesothelial and adenocarcinoma cells-an aid to cell identification. Am J Clin Pathol 1984; 81: 442–446.Google Scholar
  106. 105.
    Kahn HJ, Hanna W, Yeger H, Baumal R. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions: comparison with intermediate filament distribution by electronmicroscopy. Am J Pathol 1982; 109: 206 – 214.PubMedGoogle Scholar
  107. 106.
    Kahn H_J, Thorner PS, Yeger H, Bailey D, Baumal R. Distinct keratin patterns demonstrated by immunoperoxidase staining of adenocarcinomas, carcinoids and mesotheliomas using polyclonal and monoclonal anti-keratin antibodies. Am J Clin Pathol 1986; 86: 566 – 574.Google Scholar
  108. 107.
    Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol 1985; 9: 360 – 365.PubMedGoogle Scholar
  109. 108.
    Jasani B, Edwards RE, Thomas ND, Gibbs AR. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virchows Arch [A] 1985; 406: 441 – 448.Google Scholar
  110. 109.
    Upton MP, Hirohashi S, Tome Y, Miyazawa N, Suemasu K, Shimosato Y. Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung. Am J Surg Pathol 1986; 10: 560 – 567.PubMedGoogle Scholar
  111. 110.
    Marshall RJ, Herbert A, Braye SG, Jones DB. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma and reactive mesothelium. J Clin Pathol 1984; 37: 1215 – 1221.Google Scholar
  112. 111.
    Loosli H, Hurlimann J. Immunohistological study of malignant diffuse mesotheliomas of the pleura. Histopathology 1984; 8: 793 – 803.PubMedGoogle Scholar
  113. 112.
    Hammar SP, Bolen JW, Bockus D, Remington F, Friedman S. Ultrastructural and immunohistochemical features of common lung tumors: an overview. Ultrastruct Pathol 1985; 9: 283 – 318.PubMedGoogle Scholar
  114. 113.
    Battifora H, Kopinski MI. Distinction of mesothelioma from adenocarcinoma: an immunohistochemical approach. Cancer 1985; 55: 1679 – 1685.PubMedGoogle Scholar
  115. 114.
    Wang N-S, Huang S-N, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from lung cancer. Cancer 1979; 44: 947 – 954.Google Scholar
  116. 115.
    Whitaker D, Shilkin KB. Carcinoembryonic antigen in tissue diagnosis of malignant mesothelioma. Lancet 1981; 1: 1369.PubMedGoogle Scholar
  117. 116.
    Corson JM, Pinkus GS. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol 1982; 108: 80 – 87.PubMedGoogle Scholar
  118. 117.
    Kwee WS, Veldhuizen RW, Golding RP, et al. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis: evaluation of the application of morphometry combined with histochemistry and immunostaining. Virch Arch [A] 1982; 397: 287 – 299.Google Scholar
  119. 118.
    Said JW, Nash G, Tepper G, Banks-Schlegel S. Keratin proteins and carcinoembryonic antigen in lung carcinoma: an immunoperoxidase study of fifty-four cases with ultrastructural correlations. Hum Pathol 1983; 14: 70 – 76.PubMedGoogle Scholar
  120. 119.
    Ghosh AK, Spriggs AL, Taylor-Papadimitriou J, Mason DY. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. J Clin Pathol 1983; 36: 1154 – 1164.PubMedGoogle Scholar
  121. 120.
    Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol 1984; 8: 277 – 279.PubMedGoogle Scholar
  122. 121.
    Lee I, Rakosevich JA, Chejfec G, et al. Malignant mesotheliomas: improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44–3A6 and 624Al2. Am J Pathol 1986; 123: 497 – 507.PubMedGoogle Scholar
  123. 121a.
    Lee I, Radosevich J, Carney W et al. Immunohistochemical analysis of pulmonary and pleural neoplasms using monoclonal antibody 47D10. Lab Invest 1987; 56: 42A.Google Scholar
  124. 121b.
    Kawai T, Greenberg SD, Truong LD, Mattioli C, Klima M, Titus JL. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung. Lab Invest 1987; 56: 36A.Google Scholar
  125. 122.
    Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: an immunohistologic analysis demonstrating the value of Leu M 1 antigen. Am J Pathol 1986; 123: 21 2219.Google Scholar
  126. 123.
    Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986; 122: 252 – 260.PubMedGoogle Scholar
  127. 124.
    Suzuki Y, Churg J, Kannerstein M. Ultrastructure of human malignant diffuse mesothelioma. Am J Pathol 1976; 85: 241 – 262.PubMedGoogle Scholar
  128. 125.
    Stoebner P, Bernaudin JF, Nebut M, Basset F. Contribution of electron microscopy to the diagnosis of pleural mesothelioma. Ann NY Acad Sci 1979; 330: 751 – 760.PubMedGoogle Scholar
  129. 126.
    Kay S, Silvergerg SG. Ultrastructural studies of a malignant fibrous mesothelioma of the pleura. Arch Pathol Lab Med 1971; 92: 449 – 455.Google Scholar
  130. 127.
    Wang N-S. Electron microscopy in the diagnosis of pleural mesotheliomas. Cancer 1973; 31: 1046 – 1054.PubMedGoogle Scholar
  131. 128.
    Bolen JW, Thorning D. Mesotheliomas. A light and electron-microscopical study concerning histogenetic relationships between the epithelial and mesenchymal variants. Am J Surg Pathol 1980; 4: 451 – 464.PubMedGoogle Scholar
  132. 129.
    Klima M, Bossart MI. Sarcomatous type of malignant mesothelioma. Ultrastruct Pathol 1983; 4: 349 – 358.PubMedGoogle Scholar
  133. 130.
    d’Andiran G, Gabbiani G. A metastasing sarcoma of the pleura composed of myofibroblasts. In: Fenoglio CM, Wolff M, eds. Progress in surgical pathology. New York: Mason, 1980: 31 – 40.Google Scholar
  134. 131.
    Doucet J, Dardick I, Srigley JR, van Nostrand AWP, Bell MA, Kahn HJ. Localized fibrous tumor of serosal surfaces: immunohistochemical and ultrastructural evidence for a type of mesothelioma. Virchows Arch [A] 1986; 409: 349 – 363.Google Scholar
  135. 132.
    Epstein JI, Budin RE. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma. Hum Pathol 1986; 17: 514 – 519.PubMedGoogle Scholar
  136. 133.
    Erlandson RA, Cordon-Cardo C, Melamed MR. Proposed classification of pleural neoplasms. Lab Invest 1986; 54: 19A.Google Scholar
  137. 133a.
    el-Naggar A, Ward RM, Ro JY, Ayala AG, Ordonez NG. Fibrous tumor with hemangiopericytic pattern, so called “localized fibrous tumor of pleura. ” Lab Invest 1987; 56: 21A.Google Scholar
  138. 134.
    Warhol MJ, Hickey WF, Corson JM. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma. 1982; 6: 307 – 314.Google Scholar
  139. 135.
    Warhol MJ, Corson JM. An ultrastructural comparison of mesotheliomas with adenocarcinomas of the lung and breast. Hum Pathol 1985; 16: 50 – 55.PubMedGoogle Scholar
  140. 136.
    Burns TR, Greenberg SD, Mace ML, Johnson EH. UItrastructural diagnosis of epithelial malignant mesothelioma. Cancer 1985; 56: 2036 – 2040.PubMedGoogle Scholar
  141. 137.
    Raftery AT. Regeneration of parietal and visceral peritoneum. An electron microscopical study. J Anat 1973; 115: 375 – 392.Google Scholar
  142. 138.
    Schurch W, Seemayer TA, Legace R, Gabbiani G. Intermediate filament cytoskeleton of myofibroblasts: an immunofluorescence and ultrastructural study. Lab Invest 1984; 50: 52A.Google Scholar
  143. 139.
    Majno G. The story of the myofibroblast. Am J Surg Pathol 1979; 3: 535 – 542.PubMedGoogle Scholar
  144. 140.
    Roberts GH. Diffuse pleural mesothelioma. A clinical and pathological study. Br J Dis Chest 1970; 64: 20 1211.Google Scholar
  145. 141.
    O’Donnell WM, Mann RH, Grosh JL. Asbestos, an extrinsic factor in the pathogenesis of bronchogenic carcinoma and mesothelioma. Cancer 1966; 19: 1143 – 1148.PubMedGoogle Scholar
  146. 142.
    Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63: 695 – 702.PubMedGoogle Scholar
  147. 143.
    Harwood TR, Gracey DR, Yokoo H. Psuedomesotheliomatous carcinoma of the lung: a variant of peripheral lung cancer. Am J Clin Pathol 1976; 65: 159 – 167.PubMedGoogle Scholar
  148. 143a.
    CibasES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol 1987; 18: 67 – 74.Google Scholar
  149. 144.
    McCaughey WTE, Darkick I, Barr RJ. Angiosarcomas of serous membranes. Arch Pathol Lab Med 1983; 107: 304 – 307.PubMedGoogle Scholar
  150. 145.
    Willen R, Bruce T, Dahlstrom G, Dubiel WT. Squamous epithelial cancer in metaplastic pleura following extra-pleural pneumothorax for pulmonary tuberculosis. Virchows Arch [A] 1976; 370: 225 – 231.Google Scholar
  151. 146.
    Crome L. Squamous metaplasia of the peritoneum. J Pathol Bacteriol 1950; 62: 61 – 68.PubMedGoogle Scholar
  152. 147.
    Kwee WS, Veldhuizen RW, Golding RP, Donner R. Primary “adenosquamous” mesothelioma of the pleura. Virchows Arch [A] 1981; 393: 353 – 357.Google Scholar
  153. 148.
    Unger KM, Raber M, Bedrossian CWM, Stein DA, Barlogie B. Analysis of pleural effusions using automated flow cytometry. Cancer 1983; 52: 873 – 877.PubMedGoogle Scholar
  154. 149.
    Falor WH, Ward RM, Brezler MR. Diagnosis of pleural effusions by chromosome analysis. Chest 1982; 81: 193197.Google Scholar
  155. 150.
    Friman C, Hellstrom PE, Juvani M, Riska H. Acid glycosaminoglycans (mucopolysaccharides) in the differential diagnosis of pleural effusion. Clin Chim Acta 1977; 76: 357 – 361.PubMedGoogle Scholar
  156. 151.
    Arai H, Kang K, Sato H, et al. Significance of the quantification and demonstration of hyaluronic acid in tissue specimens for the diagnosis of pleural mesothelioma. Am Rev Respir Dis 1979; 120: 529 – 532.PubMedGoogle Scholar
  157. 152.
    Castor CW, Naylor B. Acid mucopolysaccharide composition of serous effusions. Cancer 1967; 20: 462 – 466.PubMedGoogle Scholar
  158. 153.
    Rasmussen KN, Faber V. Hyaluronic acid in 247 pleural fluids. Scand J Respir Dis 1967; 48: 366 – 371.Google Scholar
  159. 154.
    Thompson ME, Bromberg PA, Amenta JS. Acid muco-polysaccharide determination: a useful adjunct for the diagnosis of malignant mesothelioma with effusion. Am J Clin Pathol 1969; 52: 335 – 339.PubMedGoogle Scholar
  160. 155.
    Chiu B, Churg A, Tengblad A, Pearce R, McCaughey WTE. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer 1984; 54: 2195 – 2199.PubMedGoogle Scholar
  161. 156.
    Nakano T, Fujii J, Tamura S, et al. Glycosaminoglycan in malignant pleural mesothelioma. Cancer 1986; 57: 106 – 110.PubMedGoogle Scholar
  162. 157.
    Iozzo RV. Biology of disease. Proteoglycans: structure, function and role in neoplasia. Lab Invest 1985; 53: 373–396.Google Scholar
  163. 158.
    Iozzo RV, Goldes JA, Chen W-J, Wight JN. Glycosaminoglycans of pleural mesothelioma: a possible biochemical variant containing chondroitin sulfate. Cancer 1981; 48: 89 – 97.PubMedGoogle Scholar
  164. 159.
    Antman KH. Current concepts: malignant mesothelioma. N Engl J Med 1980; 303: 200 – 202.PubMedGoogle Scholar
  165. 160.
    Butchart EG, Ashcroft T, Barnsley WC, Holden M. The role of surgery in diffuse malignant mesothelioma of the pleura. Semin Oncol 1981; 8: 321 – 328.PubMedGoogle Scholar
  166. 161.
    Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68: 356 – 362.PubMedGoogle Scholar
  167. 162.
    Elmes PC, Simpson MJC. The clinical aspects of mesothelioma. Q J Med 1976; 45: 427 – 449.PubMedGoogle Scholar
  168. 163.
    Worn H. Moglichkeiten und Ergebnisse der chirugischen Behandlung des malignen Pleura mesothelioms. Thoraxchirurgie 1974; 22: 391 – 393.Google Scholar
  169. 164.
    Wanebo HJ, Martini N, Melamed MR, Hilaris B, Beattie EJ Jr. Pleural mesothelioma. Cancer 1976; 38: 2481 – 2488.Google Scholar
  170. 165.
    DeLaria GA, Jensik R, Faber P, Kittle F. Surgical management of malignant mesothelioma. Ann Thorac Surg 1978; 26: 375 – 382.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Samuel P. Hammar
  • John W. Bolen

There are no affiliations available

Personalised recommendations